Financials | Laurus Labs

INVESTORS / Financials

Audited financial statements, investor presentations and annual reports

Q1 FY 2023

Q1 FY 23 Earnings call Transcript

Audio Recording of the Q1 FY23 Results conference call hosted on July 28, 2022

Audio Recording of Results Call Q1 FY 2023

Approval of Un-audited Financial Results for the Quarter ended June 30, 2022

Investors/ Analysts Presentation

Q4 FY 2022

Audio Recording of Results Call Q4 FY 2022

Approval of audited Financial Results for the Year ended March 31, 2022 and Limited Reviewed Financial Results for the Quarter ended March 31,2022

Q4 Investor Presentation FY 2022

Q3 FY 2022

Approval of unaudited Financial Results for the Quarter and Nine months ended December 31, 2021

Audio recording of Earnings call for Q3 9M FY 22

Laurus Labs Financial Results Q3 FY 2022 Investor Presentation FINAL

Q2 FY 2022

Q2 FY 22 Earnings call Transcript

Audio recording of Earnings call for Q2 FY 22 Financial Results – October 29, 2021

Laurus Labs Financial Results Q2 FY 2022

Laurus Labs Financial Results Q2 FY 2022 Investor Presentation

Q1 FY 2022

Laurus Labs Financial Results Q1 FY 2022

Laurus Labs Financial Results Q1 FY 2022 Investor Presentation

Laurus Labs Ltd. Q1 FY 2022 Earnings Conference Call

Q4 FY 2021

Laurus Labs Financial Results Q4 FY 2021

Laurus Labs Financial Results Q4 FY 2021 Investor Presentation

Laurus Labs Q4 FY 2021 Earnings Conference Call Hosted by Ambit Capital Private Limited

Q3 FY 2021

Laurus Labs Financial Results Q3 FY 2021

Laurus Labs Financial Results Q3 FY 2021 Investor Presentation

Q3 FY 21 Results call transcript

Q2 FY 2021

Q2 FY 21 Concall Transcript

Laurus Labs Financial Results Q2 FY 2020-21

Q3 FY 21 Results call transcript

Q1 FY 2021

Laurus Labs Q1Financials FY2021

Laurus Labs Investor Presentation Q1 FY 2021

Q1 FY21 Concall Transcript

Q4 FY 2020

Q4 FY 2020: Financial Statements

Q4 FY 2020: Investor Presentation

Q4 FY 2020: Call Transcript

Q3 FY 2020

Q3 FY 2020: Financial Statements

Q3 FY 2020: Investor Presentation

Q2 FY 2020

Q2 FY 2020: Financial Statements

Q2 FY 2020: Investor Presentation

Q1 FY 2020

Q1 FY 2020: Financial Statements

Q1 FY 2020: Investor Presentation

Q4 FY 2019

Q4 & FY 2018-19: Financial Statements

Q4 & FY 2018-19: Investor Presentation

Q3 FY 2019

Q3 & FY 2018-19: Financial Statements

Q3 & FY 2018-19: Investor Presentation

Q2 FY 2019

Q2 & FY 2018-19: Financial Statements

Q2 & FY 2018-19: Investor Presentation

Q1 FY 2019

Q1 & FY 2018-19: Financial Statements

Q1 & FY 2018-19: Investor Presentation

Q4 FY 2018

Q4 & FY 2017-18: Financial Statements

Q4 & FY 2017-18: Investor Presentation

Q3 FY 2018

Q3 & FY 2017-18: Financial Statements

Q3 & FY 2017-18: Investor Presentation

Q2 FY 2018

Q2 FY 2017-18: Financial Statements

Q2 FY 2017-18: Investor Presentation

Q1 FY 2018

Q1 FY 2017-18: Financial Statements

Q1 FY 2017-18: Investor Presentation

Q4 FY 2017

Q4 & FY 2016-17: Financial Statements

Q4 & FY 2016-17: Investor Presentation

Q3 FY 2017

Q3 FY 2016-17: Standalone Financial Results Limited Review Report

Q3 FY 2016-17: Investor Presentation

FY 2021-22

Draft LLL Form_MGT_7 FY22

Laurus Labs Annual Report FY 2021-22

Laurus Labs 17th AGM Notice FY 2021-22

Laurus Labs 17th Annual General Meeting (AGM) held on 30 June, 2022

FY 2020-21

List of Shareholders as on March 31, 2021

Sustainability Report 2020-21

Laurus Labs Form MGT-7 FY 2020-21

CSR Activities FY 22

Annual Report FY 2020-21

AGM Notice FY 2020-21

Laurus Labs 16th Annual General Meeting (AGM) held on 15 July, 2021

FY 2019-20

Laurus Labs Addendum to AGM Notice 2020

Annual Report FY 2019-20

AGM Notice FY 2019-20

Annual Return Form MGT - 7

Sustainability Report FY 2019-20

Video of Laurus Labs Limited AGM held on 9 July 2020

FY 2018-19

Annual Report FY 2018-19

FY 2017-18

Annual Report FY 2017-18

AGM Notice FY 2017-18

Sustainability Report 2017-2018

FY 2016-17

Annual Report FY 2016-17

AGM Notice FY 2016-17

FY 2015-16

Annual Report FY 2015-16

FY 2014-15

Annual Report FY 2014-15

FY 2013-14

Annual Report FY 2013-14

FY 2021-22

SRIAM LABS Financiials FY 2021-22

LG GmbH Financials FY22

Laurus Generics SA Financials FY 2020-21

LHL Consolidated Financials FY22

LSPL Finanacials FY22

LGI Financials FY22

LHL Standalone Financials FY22

Laurus Bio Ind AS Financials as on March 22

Immuno IND AS Financials Mar 31 2022

FY 2020-21

SRIAM LABS Financiials FY 2020-21

Laurus Syntheiss Private Limited Financials FY 2020-21

Laurus Generics SA Financials FY 2020-21

Laurus Bio Financials FY 2020-21

Laurus Holdings Standalone Financials FY 2020-21

Laurus Holdings Consolidated Financials FY 2020-21

Laurus Generics GmbH Financials FY 2020-21

Laurus Generics Inc Financials FY 2020-21

FY 2019-20

SRIAM Ind AS Financials

LSI Ind AS Financials

LHL Ind AS Standalone Financials

LHL Ind AS Consolidated Financials

LGI Ind AS Financials

LGGmbH Ind AS Financials

FY 2018-19

Sriam Labs Pvt Ltd-Audited Financials

Laurus Synthesis Inc Audited Financials INR

Laurus Holdings Ltd Audited Financials INR

Laurus Holdings Ltd Audited Financials GBP

Laurus Generics Inc-Audited Financials

Laurus Generics GmbH-Audited Financials

FY 2017-18

Sriam Labs Pvt Ltd-Audited Financials

Laurus Synthesis Inc Audited Financials INR

Laurus Synthesis Inc Audited Financials USD

Laurus Holdings Ltd Audited Financials INR

Laurus Holdings Ltd Audited Financials GBP

Laurus Generics Inc-Audited Financials

Laurus Generics GmbH-Audited Financials

FY 2016-17

Laurus Synthesis Inc-Audited Financials

Sriam Labs Pvt Ltd-Audited Financials

FY 2015-16

Laurus Synthesis, Inc Audited Financial Statements

Discover more

Annual Report

We are making great progress on our strategic goals. See our latest annual report.

Laurus Labs 16th Annual General Meeting (AGM) held on 15 July, 2021

Find out more about us

Strengths & Strategy

We are building on our strengths to further extend our product portfolio and target fast-growing segments.

Research & Development

As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases.

Corporate Sustainability

As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community.